ClinicalTrials.gg
CompletedNCT07658521PACTUpdated Nov 2, 2026

Combined SPSP and TTP Blocks for Postoperative Analgesia Post-CABG

An interventional study of Bilateral Posterior Superior Plane Block and Bilateral Transversus Thoracic Plane in Postoperative Pain Following Coronary Artery Bypass Grafting (CABG), sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 2, 2026Now CompletedStudy documents posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.

Enrollment
97th of 364
100 · median 70
Started
2026
with 21 others
No phase
111 of 364
26 open now
Registered
347th of 364
by date
Lead sponsor
8 of 364
Ain Shams University

Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 97th largest by enrollment, is one of 22 that started in 2026, is one of 111 with no phase, and was the 347th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About bupivacaine

Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 364 studies testing bupivacaine in Pain, Postoperative, or all of them as a file.
02

Study summary

After heart bypass surgery (coronary artery bypass grafting, CABG), the breastbone is divided to reach the heart, which causes significant pain. Pain can make deep breathing and coughing difficult and may slow recovery. Strong pain medicines called opioids are the usual treatment, but they can cause side effects such as drowsiness, slowed breathing, nausea, vomiting, and confusion.

This study tested whether two nerve blocks given together can reduce the need for opioids after bypass surgery. A nerve block is an injection of local anesthetic, guided by ultrasound, that numbs a specific area of the body. The two blocks are the serratus posterior superior plane (SPSP) block, which numbs the upper side and back of the chest wall, and the transversus thoracic plane (TTP) block, which numbs the front of the chest next to the breastbone. Both were placed on each side of the chest after the patient was asleep under general anesthesia and before surgery began.

Adults aged 18 to 75 having planned (non-emergency) bypass surgery were randomly assigned, by chance, to one of two groups. One group received both blocks plus standard pain medicines. The other group received standard pain medicines alone. Patients did not know which group they were in, and the staff who measured outcomes were also unaware of group assignment.

The main question was how much opioid medicine patients needed in the first 48 hours after the breathing tube was removed. Other measures included pain scores at rest and with movement, time until first rescue pain medicine, time to breathing-tube removal, oxygen levels, length of ICU and hospital stay, time to first getting out of bed, patient satisfaction, and side effects such as complications from the blocks or from opioids.

The results may help doctors decide whether combining these two blocks is a useful way to control pain and reduce opioid use after heart bypass surgery.

Read the detailed description

Rationale. Opioid-centered analgesia after CABG delays recovery, and thoracic epidural analgesia is generally avoided in patients who are fully anticoagulated. The SPSP block covers the lateral and posterior chest wall, and the TTP block covers the anterior parasternal region. Their combined use had not been evaluated in a prospective randomized trial in cardiac surgery.

Hypothesis. Combined bilateral SPSP and TTP blocks lower 48-hour postoperative opioid consumption compared with standardized systemic analgesia alone in elective isolated CABG.

Design. Single-center, prospective, parallel-group, superiority randomized controlled trial with 1:1 allocation. Randomization used a computer-generated permuted block sequence (block sizes 4 and 6) prepared by a statistician not involved in care. Allocation was concealed with sequentially numbered, opaque, sealed envelopes, opened after induction of anesthesia.

Blinding. Patients (blocks were placed under general anesthesia) and all outcome assessors were blinded. The performing anesthesiologist could not be blinded and took no part in postoperative care, outcome assessment, data collection or analysis. Study syringes were labeled "Study Injection". Local wound infiltration was prohibited in both groups, and compliance was checked against anesthesia and nursing records. No sham procedure was used.

Standardization. Intraoperative and postoperative analgesia followed one protocol in both groups, including rescue criteria and conversion of all opioids to morphine milligram equivalents (MME). Intraoperative opioid doses were recorded separately and excluded from the primary outcome.

Block success. Assessed once, after extubation, by a blinded assessor using cold and pinprick testing over the expected dermatomes. Success rates were reported descriptively and defined the per-protocol population.

Safety monitoring. Resuscitation equipment and lipid emulsion were available at the bedside, with continuous ECG, arterial pressure, and SpO₂ monitoring. Block sites were inspected at 30 min, 6 h, and 24 h, and lung ultrasound was used for new desaturation or respiratory distress.

Statistical analysis. Intention-to-treat was primary. The primary outcome was compared with the Mann-Whitney U test (Hodges-Lehmann estimate with 95% CI), with ANCOVA adjusted for intraoperative opioid consumption as a sensitivity analysis. Secondary outcomes were prespecified, not powered, and considered hypothesis-generating.

Sample size. The target of 100 (50 per group) was set before enrollment, exceeding the originally calculated 88, to allow for block failure and to improve precision of secondary estimates.

Reporting. CONSORT 2025.

03

Conditions studied

  • Postoperative Pain Following Coronary Artery Bypass Grafting (CABG)

Browse trials for

Keywords

  • Coronary Artery Bypass
  • Nerve Block
  • Pain, Postoperative
  • Analgesics, Opioid
  • Enhanced Recovery After Surgery
  • Thoracic Wall
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-65 years.
  • Scheduled for elective, isolated CABG via median sternotomy.
  • (ASA) physical status II-III.
  • Ability to understand the study procedures, provide written , and reliably report pain scores using the NRS.

Exclusion criteria

Exclusion Criteria:

  • Emergency surgery or pre-operative hemodynamics instability.
  • Known allergies or to local anesthetics, paracetamol, morphine, or any study medication.
  • Coagulopathy, uncontrolled bleeding risk, or therapeutic anticoagulation that cannot be safely withheld per institutional guidelines ( > 1.5; \< 100 × 10⁹/L at time of block).
  • Local infection or cellulitis at any planned injection site on the anterior or lateral chest wall.
  • Pre-existing chronic pain syndrome requiring daily opioid analgesia or known opioid dependence.
  • Significant cognitive impairment, severe psychiatric disorder, or inability to reliably use pain scales.
  • History of prior thoracic surgery or major chest wall deformity distorting anatomy or limiting the ultrasound window.
  • Pregnancy or breastfeeding.
  • Any other condition judged by the investigator to represent unacceptable risk or preclude study participation.
  • Patient refusal or withdrawal of consent.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Combined SPSP + TTP Block

    Participants receive bilateral ultrasound-guided serratus posterior superior (SPSP) plane block and bilateral transversus thoracic plane (TTP) block.

    Procedure: Bilateral Posterior Superior Plane Block · Procedure: Bilateral Transversus Thoracic Plane · Drug: Conventional Systemic Analgesia · Drug: Bupivacaine 0.25%

  • Active comparator
    Conventional Analgesia Group

    Participants receive standardized multimodal systemic analgesia alone without any regional anesthesia blocks.

    Drug: Conventional Systemic Analgesia

Interventions

  • ProcedureBilateral Posterior Superior Plane Block

    With the patient in slight lateral tilt (15-20°), the trapezius (superficial), rhomboid major/minor, and the fascial plane deep to the rhomboids overlying the serratus posterior superior muscle at T2 to T5 were identified. Using a 22-gauge, 50-80 mm echogenic needle (Stimuplex Ultra 360, B. Braun) and an in-plane lateral-to-medial approach, after negative aspiration and a 1 mL test dose, 15 mL of 0.25% bupivacaine per side was deposited incrementally, confirming fascial spread under continuous ultrasound guidance. The procedure was repeated on the contralateral side.

  • ProcedureBilateral Transversus Thoracic Plane

    With the patient supine, a parasternal short-axis scan was performed at the second-fourth intercostal space level. The pectoralis major (superficial), internal intercostal muscle, and transversus thoracic muscle (deep) were identified. Using a 22-gauge, 50-80 mm echogenic block needle (Stimuplex Ultra 360, B. Braun) and an in-plane approach, after negative aspiration and a 1 mL test dose, 15 mL of 0.25% bupivacaine per side was deposited in 3-5 mL increments with intermittent aspiration, confirming fascial spread (downward displacement of the pleura). The procedure was repeated on the contralateral side.

  • DrugConventional Systemic Analgesia

    Standardized multimodal systemic analgesia regimen administered to both groups. Intraoperative: fentanyl 5-10 mcg/kg at induction with supplemental 1-2 mcg/kg boluses as needed. Postoperative: paracetamol 1 g every 6 hours from ICU arrival. A continuous intravenous fentanyl infusion commenced at 0.5 μg/kg/h once the patient emerged from anesthesia and NRS assessment became feasible. The fentanyl infusion weaned by 25% every hour prior to planned extubation and discontinued at extubation. Intravenous morphine was administered in incremental doses of 2-3 mg every 10 minutes when the NRS score was ≥4, with repeated doses until satisfactory analgesia (NRS ≤3) was achieved. Additional rescue doses of 1-2 mg were provided as required based on subsequent pain assessments.

  • DrugBupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Local anesthetic administered for regional blocks; total dose up to 2.5 mg/kg (maximum 150 mg for patients ≥65 kg, adjusted for lower weights)

06

What researchers measure

Primary outcomes

  1. Accumulated from time of tracheal extubation through 48 hours post-extubation

    Cumulative intravenous morphine milligram equivalents (MME) from tracheal extubation (time 0) to 48 hours post-extubation. All opioid doses administered during this period will be recorded and converted to IV MME using standardized conversion ratios: fentanyl 1 mcg IV = 0.1 mg IV morphine equivalent; hydromorphone 1 mg IV = 5 mg IV morphine equivalent; oxycodone 1 mg oral = 1.5 mg IV morphine equivalent; tramadol 1 mg IV = 0.1 mg IV morphine equivalent. The primary analysis will compare total 48-hour MME between the combined SPSP + TTP block group and the conventional analgesia group.

    Time frame: rom time of tracheal extubation until administration of first rescue IV morphine dose for NRS ≥ 4, assessed up to 48 hours post-extubation

Secondary outcomes

  1. NRS pain score at rest

    Numeric Rating Scale (0 = no pain, 10 = worst imaginable pain) assessed at rest at extubation (0 h), 6 h, 12 h, 24 h, and 48 h post-extubation.

    Time frame: Assessed at extubation (0 h), 6 hours, 12 hours, 24 hours, and 48 hours post-extubation

  2. NRS pain score on movement/coughing

    Numeric Rating Scale (0-10) assessed during deep inspiration, coughing, or turning in bed at 0 h, 6 h, 12 h, 24 h, and 48 h post-extubation.

    Time frame: Assessed at extubation (0 h), 6 hours, 12 hours, 24 hours, and 48 hours post-extubation

  3. Time to first rescue analgesic

    Minutes from tracheal extubation to first administration of rescue opioid for Numeric Rating Scale ≥ 4 at rest or on patient demand. Rescue protocol: IV morphine 2-3 mg every 5-10 minutes titrated to NRS ≤ 3. Recorded by blinded ICU nursing staff.

    Time frame: From time of tracheal extubation until administration of first rescue IV morphine dose for NRS ≥ 4, assessed up to 48 hours post-extubation

  4. Time to tracheal extubation

    Minutes from end of surgery (skin closure) to successful tracheal extubation in the intensive care unit. Successful extubation defined as removal of endotracheal tube with spontaneous breathing maintained for at least 30 minutes without reintubation.

    Time frame: From end of surgery (skin closure) until successful removal of endotracheal tube and spontaneous breathing without ventilatory support, assessed up to 48 hours

  5. Arterial oxygenation (PaO₂/FiO₂ ratio)

    Arterial oxygen tension to inspired oxygen fraction ratio measured at 6 hours and 24 hours post-extubation

    Time frame: Assessed at 6 hours and 24 hours post-extubation

  6. Incidence of atelectasis

    incidence of atelectasis (radiographic confirmation)

    Time frame: From time of tracheal extubation until hospital discharge or postoperative day 30, whichever occurs first

  7. Incentive spirometry volume

    Volume achieved with incentive spirometry in millilitres at 24 and 48 hours post-extubation. Assessed by a blinded physiotherapist or nursing staff using standardized technique.

    Time frame: Assessed at 24 hours and 48 hours post-extubation

  8. Pulmonary complications

    Incidence of atelectasis (radiographic confirmation), pneumonia (clinical and radiographic criteria per CDC definitions), or reintubation occurring during the hospital stay. Composite binary outcome.

    Time frame: From time of tracheal extubation until hospital discharge or postoperative day 30, whichever occurs first

  9. Intensive care unit length of stay

    Hours from intensive care unit admission to ICU discharge to the ward. Discharge criteria per institutional protocol: hemodynamic stability without vasopressors, adequate oxygenation on room air or low-flow oxygen, and no active arrhythmias requiring intervention.

    Time frame: From ICU admission until ICU discharge, assessed up to 7 days postoperatively

  10. Hospital length of stay

    Days from surgery (admission) to hospital discharge. Discharge criteria per institutional protocol: ambulatory, pain controlled on oral analgesics, wound healing satisfactory, and no active medical issues requiring inpatient management.

    Time frame: From date of surgery until date of hospital discharge, assessed up to 30 days postoperatively

  11. Patient satisfaction with pain management

    Likert scale 1-5 (1 = very dissatisfied, 2 = dissatisfied, 3 = neutral, 4 = satisfied, 5 = very satisfied) assessing overall satisfaction with postoperative pain management at 48 hours post-extubation. Completed by patient with blinded assessor assistance if needed.

    Time frame: Assessed at 48 hours post-extubation using a 5-point Likert scale

  12. Time to first ambulation

    Hours from tracheal extubation to first assisted ambulation greater than 10 metres. Ambulation is defined as standing and walking with or without assistance. Recorded by blinded ICU or ward physiotherapy staff.

    Time frame: From time of tracheal extubation until first documented assisted or unassisted ambulation, assessed up to 7 days postoperatively or until hospital discharge, whichever occurs first

Other outcomes

  1. Block-related complications

    Incidence of pneumothorax (symptomatic or radiographic), local hematoma at the injection site, infection (erythema, warmth, or purulent discharge), or nerve injury in the intervention group. Monitored by clinical examination, chest auscultation, and imaging as indicated.

    Time frame: From performance of regional blocks until hospital discharge or postoperative day 30, whichever occurs first.

  2. Local anesthetic systemic toxicity

    Signs and symptoms of LAST: CNS manifestations including tinnitus, circumoral numbness, metallic taste, agitation, dizziness, or seizure; cardiovascular manifestations including arrhythmia, bradycardia, ventricular tachycardia, hypotension, or cardiac arrest.

    Time frame: From initiation of regional block injection until 24 hours post-block.

  3. Opioid-related adverse events

    Respiratory depression requiring naloxone administration; severe nausea or vomiting requiring antiemetic intervention; ileus, defined as absence of bowel sounds greater than 48 hours; urinary retention requiring catheterization, or postoperative delirium.

    Time frame: From time of tracheal extubation through hospital discharge or postoperative day 30, whichever occurs first.

07

Study locations

1 site
  • Ain Shams University Hospitals
    Cairo, Cairo Governorate 1181, Egypt
08

References and documents

Publications

  • Shokri H, Ali I, Kasem AA. Evaluation of the Analgesic Efficacy of Bilateral Ultrasound-Guided Transversus Thoracic Muscle Plane Block on Post-Sternotomy Pain: A Randomized Controlled Trial. Local Reg Anesth. 2021 Nov 12;14:145-152. doi: 10.2147/LRA.S338685. eCollection 2021. PubMed 34803399 ↗
  • Murata H, Hida K, Hara T. Transverse Thoracic Muscle Plane Block: Tricks and Tips to Accomplish the Block. Reg Anesth Pain Med. 2016 May-Jun;41(3):411-2. doi: 10.1097/AAP.0000000000000374. No abstract available. PubMed 27093277 ↗
  • Ueshima H, Hara E, Marui T, Otake H. RETRACTED: The ultrasound-guided transversus thoracic muscle plane block is effective for the median sternotomy. J Clin Anesth. 2016 Mar;29:83. doi: 10.1016/j.jclinane.2015.10.014. Epub 2016 Feb 9. No abstract available. PubMed 26897453 ↗
  • Tulgar S, Ciftci B, Ahiskalioglu A, Bilal B, Sakul BU, Korkmaz AO, Bozkurt NN, De Cassai A, Torres AJ, Elsharkawy H, Alici HA. Serratus Posterior Superior Intercostal Plane Block: A Technical Report on the Description of a Novel Periparavertebral Block for Thoracic Pain. Cureus. 2023 Feb 3;15(2):e34582. doi: 10.7759/cureus.34582. eCollection 2023 Feb. PubMed 36883093 ↗
  • Balan C, Bubenek-Turconi SI, Tomescu DR, Valeanu L. Ultrasound-Guided Regional Anesthesia-Current Strategies for Enhanced Recovery after Cardiac Surgery. Medicina (Kaunas). 2021 Mar 25;57(4):312. doi: 10.3390/medicina57040312. PubMed 33806175 ↗
  • Kelava M, Alfirevic A, Bustamante S, Hargrave J, Marciniak D. Regional Anesthesia in Cardiac Surgery: An Overview of Fascial Plane Chest Wall Blocks. Anesth Analg. 2020 Jul;131(1):127-135. doi: 10.1213/ANE.0000000000004682. PubMed 32032103 ↗
  • Kleiman AM, Sanders DT, Nemergut EC, Huffmyer JL. Chronic Poststernotomy Pain: Incidence, Risk Factors, Treatment, Prevention, and the Anesthesiologist's Role. Reg Anesth Pain Med. 2017 Nov/Dec;42(6):698-708. doi: 10.1097/AAP.0000000000000663. PubMed 28937533 ↗
  • Hamilton C, Alfille P, Mountjoy J, Bao X. Regional anesthesia and acute perioperative pain management in thoracic surgery: a narrative review. J Thorac Dis. 2022 Jun;14(6):2276-2296. doi: 10.21037/jtd-21-1740. PubMed 35813725 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying published results will be shared with qualified researchers upon reasonable request to the principal investigator, subject to approval by the Ain Shams University IRB and execution of a data use agreement.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Access criteria: Data will be available beginning 9 months after primary publication and ending 36 months thereafter.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2026 to primary completion in Sep 2026, 2 months.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 2 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2026 → Sep 2026 and completion Jan 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jun 22, 2026
StartActual
Jul 1, 2026
Primary completionActual
Sep 25, 2026was Dec 2026
CompletionActual
Sep 30, 2026was Jan 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Oct 28, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (2 Egypt)
  • Ain Shams University Hospitals · Cairo, Egypt
  • Ain Shams University Hospitals · Cairo, Egypt
Show 2 removed
  • Ain Shams University Hospitals · Cairo, Egypt
  • Ain Shams University Hospitals · Cairo, Egypt
across 2 updates, Oct 28, 2026 – Nov 2, 2026
Primary completion
Dec 31, 2026→Sep 25, 2026 (actual)
Oct 28, 2026
Study completion
Jan 15, 2027→Sep 30, 2026 (actual)
Oct 28, 2026
Enrollment
88 (estimated)→100 (actual)
Oct 28, 2026
Interventions
Added Procedure: Bilateral Posterior Superior Plane Block·Procedure: Bilateral Transversus Thoracic Plane; removed Procedure: Transversus Thoracic Plane Block·Procedure: Transversus Thoracic Plane (TTP) Block
Nov 2, 2026
Documents
Show all 2 updates
  1. Nov 2, 2026
    1 site added, 1 site removed
    Show site
    • Ain Shams University Hospitals · Cairo, Egypt
    Show 1 removed
    • Ain Shams University Hospitals · Cairo, Egypt
    Interventions Added Procedure: Bilateral Posterior Superior Plane Block·Procedure: Bilateral Transversus Thoracic Plane; removed Procedure: Transversus Thoracic Plane Block·Procedure: Transversus Thoracic Plane (TTP) Block
    + 4 other changes: index terms, description, conditions and design details
  2. Oct 28, 2026
    Enrolling by invitation→Completed
    1 site added, 1 site removed
    Show site
    • Ain Shams University Hospitals · Cairo, Egypt
    Show 1 removed
    • Ain Shams University Hospitals · Cairo, Egypt
    Primary completion Dec 31, 2026→Sep 25, 2026 (now actual)
    Study completion Jan 15, 2027→Sep 30, 2026 (now actual)
    Enrollment 88 (estimated)→100 (actual)
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07658521
Responsible party
Mohamed Alaaeldin Alhadidy (Principal Investigator, Ain Shams University) — Principal investigator
First posted
Jun 22, 2026
Start date
Jul 1, 2026
Primary completion
Sep 25, 2026
Completion
Sep 30, 2026
Last update
Nov 2, 2026

Study contacts

Nasser Elsayed Ebrahim, MD
principal investigator · Ain Shams University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion